These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 29619024)

  • 41. Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells.
    Wang L; Gong W; Wang S; Neuber B; Sellner L; Schubert ML; Hückelhoven-Krauss A; Kunz A; Gern U; Michels B; Hinkelbein M; Mechler S; Richter P; Müller-Tidow C; Schmitt M; Schmitt A
    Cytotherapy; 2019 May; 21(5):566-578. PubMed ID: 30910382
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Chimeric antigen receptor T-cell therapy for multiple myeloma].
    Hosen N
    Rinsho Ketsueki; 2018; 59(10):2189-2194. PubMed ID: 30305525
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FGFR4-specific CAR-T cells with inducible caspase-9 suicide gene as an approach to treat rhabdomyosarcoma.
    Xiao W; Xu L; Wang J; Yu K; Xu B; Que Y; Zhao J; Pan Q; Gao C; Zhou P; Zhang X
    Cancer Gene Ther; 2024 Oct; 31(10):1571-1584. PubMed ID: 39183354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.
    Xiao L; Chen C; Li Z; Zhu S; Tay JC; Zhang X; Zha S; Zeng J; Tan WK; Liu X; Chng WJ; Wang S
    Cytotherapy; 2018 Mar; 20(3):420-435. PubMed ID: 29402645
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
    Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
    Front Immunol; 2018; 9():239. PubMed ID: 29515572
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
    Ma T; Shi J; Liu H
    Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy.
    Jonnalagadda M; Mardiros A; Urak R; Wang X; Hoffman LJ; Bernanke A; Chang WC; Bretzlaff W; Starr R; Priceman S; Ostberg JR; Forman SJ; Brown CE
    Mol Ther; 2015 Apr; 23(4):757-68. PubMed ID: 25366031
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?
    Salmikangas P; Kinsella N; Chamberlain P
    Pharm Res; 2018 May; 35(8):152. PubMed ID: 29855723
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Standardizing CAR-T therapy: Getting it scaled up.
    Dai X; Mei Y; Cai D; Han W
    Biotechnol Adv; 2019; 37(1):239-245. PubMed ID: 30543841
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer.
    Kim M; Pyo S; Kang CH; Lee CO; Lee HK; Choi SU; Park CH
    PLoS One; 2018; 13(6):e0198347. PubMed ID: 29874279
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of a Fully Human, Hepatitis B Virus-Specific Chimeric Antigen Receptor in an Immunocompetent Mouse Model.
    Festag MM; Festag J; Fräßle SP; Asen T; Sacherl J; Schreiber S; Mück-Häusl MA; Busch DH; Wisskirchen K; Protzer U
    Mol Ther; 2019 May; 27(5):947-959. PubMed ID: 30852138
    [TBL] [Abstract][Full Text] [Related]  

  • 52. GMP CAR-T cell production.
    Gee AP
    Best Pract Res Clin Haematol; 2018 Jun; 31(2):126-134. PubMed ID: 29909913
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chimeric antigen receptor T cell therapies for multiple myeloma.
    Wu C; Zhang L; Brockman QR; Zhan F; Chen L
    J Hematol Oncol; 2019 Nov; 12(1):120. PubMed ID: 31752943
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.
    Qin L; Lai Y; Zhao R; Wei X; Weng J; Lai P; Li B; Lin S; Wang S; Wu Q; Liang Q; Li Y; Zhang X; Wu Y; Liu P; Yao Y; Pei D; Du X; Li P
    J Hematol Oncol; 2017 Mar; 10(1):68. PubMed ID: 28288656
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A compound chimeric antigen receptor strategy for targeting multiple myeloma.
    Chen KH; Wada M; Pinz KG; Liu H; Shuai X; Chen X; Yan LE; Petrov JC; Salman H; Senzel L; Leung ELH; Jiang X; Ma Y
    Leukemia; 2018 Feb; 32(2):402-412. PubMed ID: 28951562
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization of CAR T cell expansion and cytotoxic potential during Ex Vivo manufacturing using image-based cytometry.
    Maldini CR; Love AC; Tosh KW; Chan LL; Gayout K; Smith T; Riley JL
    J Immunol Methods; 2020; 484-485():112830. PubMed ID: 32745474
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.
    Baumeister SH; Murad J; Werner L; Daley H; Trebeden-Negre H; Gicobi JK; Schmucker A; Reder J; Sentman CL; Gilham DE; Lehmann FF; Galinsky I; DiPietro H; Cummings K; Munshi NC; Stone RM; Neuberg DS; Soiffer R; Dranoff G; Ritz J; Nikiforow S
    Cancer Immunol Res; 2019 Jan; 7(1):100-112. PubMed ID: 30396908
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
    Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
    Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 60. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
    Cohen AD; Garfall AL; Stadtmauer EA; Melenhorst JJ; Lacey SF; Lancaster E; Vogl DT; Weiss BM; Dengel K; Nelson A; Plesa G; Chen F; Davis MM; Hwang WT; Young RM; Brogdon JL; Isaacs R; Pruteanu-Malinici I; Siegel DL; Levine BL; June CH; Milone MC
    J Clin Invest; 2019 Mar; 129(6):2210-2221. PubMed ID: 30896447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.